Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • 11 March 2014

    Risk of dying is revealed among healthy people !

    Novel biological markers have discovered by researchers from Finland and Estonia  that are strongly indicative of risk of dying from any disease within the near future. Blood samples from over 17000 generally healthy people were screened for more than a hundred different biomolecules. The health status of these study volunteers was followed for several years. The researchers looked for measures in the blood that could reflect who had died within the following 5 years after the blood sample was taken. In a study published in PLOS Medicine, they describe identification of four such biomarkers of death.

  • 26 February 2014
    Collaboration in pharmacovigilance strengthen by FDA and EMA

    A new "cluster" have set up on medicinal safety topics by join efforts of U.S. Food and Drug Administration and the European Medicines Agency (EMA). Clusters are regular collaborative meetings between the EMA and regulators outside of the European Union, which focus on specific topic areas that have been identified as requiring an intensified exchange of information and collaboration.

  • 25 February 2014
    Government releases National Guidelines for Stem Cell Research

    Basic guidelines for stem cell research were released in 2007 by joint efforts of DBT & ICMR which are revised in December 2013 after evaluating development in field of stem cell research. These newer guidelines are termed as 'National Guidelines for Stem Cell Research'.

  • 20 February 2014
    Expert Committee recommends amendment of D&C act and include SCCPs as new drug

    The expert committee submitted report to ministry of health and family welfare, Government of India on amendment of relevant rules in the Drugs and Cosmetics Act 1940 to include stem cells and other cell based products (SCCPs) as New Drugs.

  • 20 February 2014
    Appointment of Dr. Kiran Mazumdar Shaw as the Chairperson of IIM-B

    Indian Institute of Management, Bangalore (IIM-B) is announced the appointment of Dr. Kiran Mazumdar Shaw, Chairman and Managing Director of Biocon Limited, as the Chairperson of its Board of Governors. She takes over from Mr. Mukesh D Ambani and became the first woman Chairperson of any IIM Board.

  • 19 February 2014
    New Drug Approval for treatment of neurogenic orthostatic hypotension

    The USFDA approved Chelsea Therapeutics's product Northera capsules (droxidopa), orphan-product, for the treatment of neurogenic orthostatic hypotension (NOH) which is rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson's disease, multiple-system atrophy,

  • 19 February 2014
    Government to introduce Third Line Treatment of HIV/AIDS in 10 ART Centres across the country

    Presently, the first line and second line antiretroviral therapy (ART) is given to HIV/AIDS patients free of cost in all ART Centres across the country. The Technical Resource Group on ART on 27th December, 2013 recommended providing third line antiretroviral therapy for HIV/AIDS patients through 10 centres of excellence across the country. The process for the same has been initiated at Department of AIDS Control.

  • 13 February 2014
    IMBRUVICA™ gets nod from USFDA for treatment of Chronic Lymphocytic Leukemia - rare blood and bone marrow disease

    The U.S. Food and Drug Administration expanded the approved use of Imbruvica™ which contains ibrutinib, for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy on Wednesday, 12 Feb, 2014. Imbruvica™ is manufactured by Pharmacyclics based at Sunnyvale, California.

  • 11 February 2014
    Lower-intensity statin combination therapy may utilize for high-risk atherosclerotic cardiovascular disease

    For atherosclerotic cardiovascular disease risk reduction, American College of Cardiology and the American Heart Association guidelines recommend initiating moderate or high-intensity statin monotherapy as the first-lin

  • 11 February 2014
    Mast Therapeutics acquire Aires Pharmaceuticals, Inc.

    Mast Therapeutics, Inc., publicly traded biopharmaceutical company headquartered in San Diego, California, announced on 10th feb, 2014 that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure.

Subscribe to Pharma News